Ohio Lands $750 Million Expansion to Produce Lilly Weight Loss Injection Pens

Ohio Expansion Will Increase Production of Lilly Injection Pens

Eli Lilly and pharmaceutical manufacturer Resilience have announced a $750 million investment in the Cincinnati region that will expand production of injection devices used with diabetes and obesity medicines and create at least 400 jobs. The expansion will add production of Lilly’s KwikPen injection device at Resilience’s manufacturing operations in West Chester Township. Site preparation is underway, and the companies expect the expanded operation to be fully running in early 2027. The companies did not disclose how the investment will be divided between Lilly and Resilience or how much will be used for construction, equipment, automation and other expenses.

The project expands a manufacturing partnership that began in 2023. Resilience said the partnership has already produced more than 150 million doses of Lilly medicines for patients in the United States through vial and prefilled syringe manufacturing. Adding KwikPen production will give the Ohio operation a larger role in manufacturing the devices patients use to administer injectable medicines, although the companies have not identified which individual Lilly products will be handled at the expanded West Chester facility.

The investment comes as demand for diabetes and obesity medicines continues to grow rapidly. That growth is not simply the result of Americans suddenly becoming dramatically less healthy. Obesity and diabetes were already affecting tens of millions of people before the newest generation of medicines became widely available. What changed more quickly was the effectiveness of the treatment options available to those patients.

Lilly’s Zepbound contains tirzepatide, a medicine that acts on two hormone receptors involved in appetite, food intake and blood sugar regulation. It is taken once a week and is approved for adults with obesity, along with certain adults who are overweight and have related medical conditions. In a clinical study reviewed by the Food and Drug Administration involving adults who did not have type 2 diabetes, patients receiving the highest approved dose of Zepbound lost an average of 20.9 percent of their starting body weight after 72 weeks. Patients receiving a placebo lost an average of 3.1 percent. Participants in both groups were also instructed to follow a reduced calorie diet and increase physical activity. Individual results can vary, and the medicine can cause side effects.

That level of average weight reduction has made prescription obesity treatment attractive to people who previously struggled to achieve similar results through diet, exercise or earlier medicines. Federal health data show that about 40 percent of American adults have obesity. The overall adult obesity rate did not increase significantly during the most recent decade of nationally measured data, although severe obesity became more common. Those findings suggest that the recent surge in demand is not being driven primarily by a sudden increase in the number of Americans with obesity. Instead, a large population that was already living with the condition gained access to a treatment capable of producing weight loss that was difficult to achieve with many previous prescription options.

The number of patients who could potentially use Zepbound has also grown as the FDA approved additional medical uses for the medicine. In December 2024, the FDA approved Zepbound to treat moderate to severe obstructive sleep apnea in adults with obesity. It became the first medicine approved specifically for certain patients with the condition. The agency said weight reduction associated with the treatment helped reduce obstruction of the upper airway during sleep.

The increased demand is reflected in Lilly’s sales. Zepbound generated approximately $4.16 billion in revenue during the first three months of 2026, compared with about $2.31 billion during the same period in 2025, according to Lilly’s first quarter financial report. That represented an increase of approximately 80 percent in one year. The figure reflects sales revenue, not the amount Lilly retained as profit after manufacturing, research, marketing and other expenses. Lilly said the increase was primarily driven by strong demand and higher sales volume, even as reductions in some cash purchase prices lowered the average amount the company received for certain prescriptions.

The company has also expanded the ways patients can obtain and use Zepbound, including the introduction of a multidose KwikPen containing four weekly doses. Greater production capacity, improved availability and additional distribution options have allowed more patients to begin treatment. Diabetes is considerably more common among older adults, meaning the country’s aging population represents a growing potential market for diabetes treatment. Obesity, however, is most prevalent among adults ages 40 through 59, showing that demand for weight management medicines extends well beyond retirement age.

The Ohio investment is intended to help Lilly and Resilience keep pace with that demand while increasing pharmaceutical manufacturing inside the United States. Resilience operates nearly 1 million square feet of manufacturing space across two Cincinnati area facilities and recently moved its global headquarters from California to Blue Ash. The company has described its Ohio operations as part of an effort to build one of the country’s largest centers for sterile injectable manufacturing, device assembly and pharmaceutical packaging.

Resilience said the newly announced hiring will bring the number of jobs it has created in Ohio to more than 1,400. The new positions are expected to include work in manufacturing, quality control, engineering, operations, supply chain and regulatory compliance. The companies have not announced an average wage, detailed hiring schedule or complete breakdown of the 400 jobs. They also have not said how many KwikPens the expanded operation will be able to produce each year or when the first devices manufactured through the new capacity will reach patients.

The announcement credited JobsOhio, REDI Cincinnati and Ohio Life Sciences with supporting workforce development in the region, but it did not disclose whether the newly announced expansion will receive project specific grants, tax credits, abatements or other public assistance.